TRI-611 for ALK-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests an experimental pill for people with a specific type of lung cancer. The trial will see if the drug is safe and if it helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer must have a specific gene change called ALK.
- You must be able to swallow pills or capsules.
- You must not have any other serious medical condition that would make the study unsafe for you.
- You must not have had major surgery in the 4 weeks before starting the study drug.
- You must not have taken any other cancer drug or been in another clinical trial in the 4 weeks before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This trial tests a combination of two targeted therapies (lorlatinib and sacituzumab tirumotecan) as first treatment for advanced non-small cell lung cancer with an ALK gene change. The goal is to see if the combination works better than current treatments and to use a simple blood test to guide therapy.
This study tests whether giving a new targeted pill (iruplaltinib) along with chemotherapy before surgery can help shrink tumors and improve outcomes for people with ALK-positive lung cancer. Participation involves taking study drugs, having tests, and then undergoing surgery.
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
Hear when a new ALK-positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.